BIOCERES CROP SOLUTIONS CORP (BIOX) Stock Fundamental Analysis
NASDAQ:BIOX - Nasdaq - KYG1117K1141 - Common Stock - Currency: USD
BIOX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 85 industry peers in the Chemicals industry. BIOX has a bad profitability rating. Also its financial health evaluation is rather negative. BIOX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BIOX was profitable.
BIOX had a positive operating cash flow in the past year.
In multiple years BIOX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: BIOX reported negative operating cash flow in multiple years.
1.2 Ratios
BIOX has a Return On Assets of 0.18%. This is comparable to the rest of the industry: BIOX outperforms 42.35% of its industry peers.
Looking at the Return On Equity, with a value of 0.47%, BIOX is in line with its industry, outperforming 42.35% of the companies in the same industry.
BIOX has a Return On Invested Capital (4.71%) which is in line with its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIOX is in line with the industry average of 7.05%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.18% | ||
| ROE | 0.47% | ||
| ROIC | 4.71% |
ROA(3y)0.43%
ROA(5y)0.14%
ROE(3y)0.56%
ROE(5y)-0.23%
ROIC(3y)6.06%
ROIC(5y)8.13%
1.3 Margins
With a Profit Margin value of 0.33%, BIOX perfoms like the industry average, outperforming 42.35% of the companies in the same industry.
The Operating Margin of BIOX (9.09%) is comparable to the rest of the industry.
BIOX's Operating Margin has declined in the last couple of years.
BIOX's Gross Margin of 40.53% is amongst the best of the industry. BIOX outperforms 84.71% of its industry peers.
In the last couple of years the Gross Margin of BIOX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.09% | ||
| PM (TTM) | 0.33% | ||
| GM | 40.53% |
OM growth 3Y-17.81%
OM growth 5Y-13.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-2.6%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIOX is destroying value.
Compared to 1 year ago, BIOX has about the same amount of shares outstanding.
Compared to 5 years ago, BIOX has more shares outstanding
BIOX has a worse debt/assets ratio than last year.
2.2 Solvency
The Debt to FCF ratio of BIOX is 21.84, which is on the high side as it means it would take BIOX, 21.84 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 21.84, BIOX perfoms like the industry average, outperforming 49.41% of the companies in the same industry.
BIOX has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.47, BIOX is doing good in the industry, outperforming 65.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 21.84 | ||
| Altman-Z | N/A |
ROIC/WACC0.54
WACC8.67%
2.3 Liquidity
A Current Ratio of 1.27 indicates that BIOX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.27, BIOX is not doing good in the industry: 74.12% of the companies in the same industry are doing better.
BIOX has a Quick Ratio of 1.27. This is a bad value and indicates that BIOX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of BIOX (0.88) is worse than 64.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
The earnings per share for BIOX have decreased strongly by -91.19% in the last year.
BIOX shows a decrease in Revenue. In the last year, the revenue decreased by -9.77%.
BIOX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.73% yearly.
EPS 1Y (TTM)-91.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.63%
Revenue 1Y (TTM)-9.77%
Revenue growth 3Y31.01%
Revenue growth 5Y23.73%
Sales Q2Q%-23.82%
3.2 Future
The Earnings Per Share is expected to grow by 75.75% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 6.62% on average over the next years.
EPS Next Y-284.41%
EPS Next 2Y68.89%
EPS Next 3Y144.94%
EPS Next 5Y75.75%
Revenue Next Year-19.62%
Revenue Next 2Y-7.02%
Revenue Next 3Y6.27%
Revenue Next 5Y6.62%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 147.17, BIOX can be considered very expensive at the moment.
67.06% of the companies in the same industry are cheaper than BIOX, based on the Price/Earnings ratio.
BIOX is valuated expensively when we compare the Price/Earnings ratio to 28.92, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 26.23, the valuation of BIOX can be described as expensive.
BIOX's Price/Forward Earnings is on the same level as the industry average.
BIOX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 21.65, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 147.17 | ||
| Fwd PE | 26.23 |
4.2 Price Multiples
61.18% of the companies in the same industry are more expensive than BIOX, based on the Enterprise Value to EBITDA ratio.
BIOX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BIOX is cheaper than 63.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.68 | ||
| EV/EBITDA | 8 |
4.3 Compensation for Growth
BIOX's earnings are expected to grow with 144.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y68.89%
EPS Next 3Y144.94%
5. Dividend
5.1 Amount
BIOX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BIOX (4/25/2025, 10:23:09 AM)
4.415
+0.07 (+1.49%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners21.08%
Inst Owner Change-0.19%
Ins Owners1.33%
Ins Owner ChangeN/A
Market Cap276.86M
Analysts84
Price Target8.03 (81.88%)
Short Float %3.25%
Short Ratio3.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP11.93%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-594.26%
Min EPS beat(2)-1076.47%
Max EPS beat(2)-112.05%
EPS beat(4)0
Avg EPS beat(4)-321.88%
Min EPS beat(4)-1076.47%
Max EPS beat(4)-19.26%
EPS beat(8)1
Avg EPS beat(8)-34.87%
EPS beat(12)2
Avg EPS beat(12)-47%
EPS beat(16)3
Avg EPS beat(16)-49.47%
Revenue beat(2)0
Avg Revenue beat(2)-13.55%
Min Revenue beat(2)-16.91%
Max Revenue beat(2)-10.19%
Revenue beat(4)1
Avg Revenue beat(4)-6.5%
Min Revenue beat(4)-16.91%
Max Revenue beat(4)17.49%
Revenue beat(8)2
Avg Revenue beat(8)-4.43%
Revenue beat(12)6
Avg Revenue beat(12)8.19%
Revenue beat(16)9
Avg Revenue beat(16)10.74%
PT rev (1m)-24.1%
PT rev (3m)-41.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-42.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-142.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.4%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 147.17 | ||
| Fwd PE | 26.23 | ||
| P/S | 0.63 | ||
| P/FCF | 22.68 | ||
| P/OCF | 8.62 | ||
| P/B | 0.89 | ||
| P/tB | 12.85 | ||
| EV/EBITDA | 8 |
EPS(TTM)0.03
EY0.68%
EPS(NY)0.17
Fwd EY3.81%
FCF(TTM)0.19
FCFY4.41%
OCF(TTM)0.51
OCFY11.61%
SpS7.04
BVpS4.94
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.18% | ||
| ROE | 0.47% | ||
| ROCE | 7.55% | ||
| ROIC | 4.71% | ||
| ROICexc | 5.07% | ||
| ROICexgc | 12.18% | ||
| OM | 9.09% | ||
| PM (TTM) | 0.33% | ||
| GM | 40.53% | ||
| FCFM | 2.77% |
ROA(3y)0.43%
ROA(5y)0.14%
ROE(3y)0.56%
ROE(5y)-0.23%
ROIC(3y)6.06%
ROIC(5y)8.13%
ROICexc(3y)6.87%
ROICexc(5y)10.39%
ROICexgc(3y)15.77%
ROICexgc(5y)22.76%
ROCE(3y)9.78%
ROCE(5y)13.22%
ROICexcg growth 3Y-15.22%
ROICexcg growth 5Y-15.76%
ROICexc growth 3Y-21.1%
ROICexc growth 5Y-17.96%
OM growth 3Y-17.81%
OM growth 5Y-13.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-2.6%
F-Score6
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 21.84 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 91.49% | ||
| Cap/Sales | 4.52% | ||
| Interest Coverage | 1.6 | ||
| Cash Conversion | 51.92% | ||
| Profit Quality | 832.88% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | N/A |
F-Score6
WACC8.67%
ROIC/WACC0.54
Cap/Depr(3y)107.09%
Cap/Depr(5y)127.69%
Cap/Sales(3y)4.36%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-91.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.63%
EPS Next Y-284.41%
EPS Next 2Y68.89%
EPS Next 3Y144.94%
EPS Next 5Y75.75%
Revenue 1Y (TTM)-9.77%
Revenue growth 3Y31.01%
Revenue growth 5Y23.73%
Sales Q2Q%-23.82%
Revenue Next Year-19.62%
Revenue Next 2Y-7.02%
Revenue Next 3Y6.27%
Revenue Next 5Y6.62%
EBIT growth 1Y-3.48%
EBIT growth 3Y7.68%
EBIT growth 5Y7%
EBIT Next Year-13.11%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y125.7%
FCF growth 3YN/A
FCF growth 5Y-6.35%
OCF growth 1Y188.79%
OCF growth 3YN/A
OCF growth 5Y7.02%